Denise Carter - May 29, 2025 Form 4/A - Amendment Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Chief Operating Officer, Director
Signature
/s/ Denise Carter
Stock symbol
QNRX
Transactions as of
May 29, 2025
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/13/2025, 08:09 PM
Date Of Original Report
Jun 2, 2025
Previous filing
Dec 27, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Carter Denise P. Chief Operating Officer, Director C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN /s/ Denise Carter 2025-06-13 0001958621

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Share Option (Right to Buy) Award $0 +42.9K $0.00 42.9K May 29, 2025 ADS 42.9K $9.07 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.
F2 The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.